This Article Full Text (PDF) All Versions of this Article: 0897190008322290v1 22/1/65    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bruce, S. P. Search for Related Content Social Bookmarking                         What's this?

Recent Developments in the Treatment of Rheumatoid Arthritis

Department of Pharmacy Practice, Northeastern Ohio Universities College of Pharmacy, Rootstown, Ohio, sbruce{at}neoucom.edu

The introduction of biologic response modifiers has revolutionized treatment approaches in rheumatoid arthritis. The ideal treatment approach to induce remission and minimize joint destruction is yet to be determined, however. The guidelines for the treatment of rheumatoid arthritis were updated in 2008. Evidence published recently may help to guide treatment decisions. In this review, advances in treatment approaches are discussed with added emphasis on the cardiovascular risks to this patient population. New data regarding the biologic response modifiers currently available in the US, abatacept and rituximab, are reviewed. Finally, emerging therapies are introduced, including tocilizumab. Investigational agents in development may provide additional options in the future treatment of rheumatoid arthritis.

Key Words: rheumatoid arthritis • biologic response modifiers • abatacept • rituximab • tocilizumab

This version was published on February 1, 2009

Journal of Pharmacy Practice, Vol. 22, No. 1, 65-74 (2009)
DOI: 10.1177/0897190008322290


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?